Status:
COMPLETED
Long-Term Oral Acyclovir Usage to Prevent Herpes Zoster Virus Infection After Bone Marrow Transplant
Lead Sponsor:
Fred Hutchinson Cancer Center
Collaborating Sponsors:
Burroughs Wellcome
National Institutes of Health (NIH)
Conditions:
VZV Infection After Bone Marrow Transplantation
Eligibility:
All Genders
10+ years
Phase:
PHASE3
Brief Summary
The objective of this study is to prevent reactivation of herpes zoster during the first year after transplant.
Detailed Description
Herpes zoster infection occurs in 30% of allogeneic hematopoietic cell transplant (HCT) recipients who had a history of varicella zoster virus (VZV) infection. A safe and effective prevention strategy...
Eligibility Criteria
Inclusion
- 10 years or older
- Both sex (male or female)
- Allogeneic transplant patient for hematologic malignancy or aplastic anemia
Exclusion
- Previous intolerance to acyclovir
- Patients who are unavailable for follow-up
- Patients in whom drug compliance may be a problem
- Evidence of active VZV infection
- VZV infection in the initial 1 month after transplant
- Pregnant women, lactating women, or those not using adequate contraception
- Creatinine \> 3.0 mg/dl.
Key Trial Info
Start Date :
June 1 1985
Trial Type :
INTERVENTIONAL
End Date :
July 1 2004
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT00209352
Start Date
June 1 1985
End Date
July 1 2004
Last Update
December 21 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fred Hutchinson Cancer Research Center
Seattle, Washington, United States, 98109